Biofrontera Inc. (NASDAQ:BFRI): When Will It Breakeven? [Yahoo! Finance]
Biofrontera Inc. (BFRI)
Company Research
Source: Yahoo! Finance
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The US$10m market-cap company posted a loss in its most recent financial year of US$18m and a latest trailing-twelve-month loss of US$17m shrinking the gap between loss and breakeven. The most pressing concern for investors is Biofrontera's path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. According to the 2 industry analysts covering Biofrontera, the consensus is that breakeven is near. They expect the company to post a final loss in 2025, before turning a profit of US$666k in 2026. So, the company is predicted to breakeven just over a year from now. In order to meet this breakeven date, we calcul
Show less
Read more
Impact Snapshot
Event Time:
BFRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BFRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BFRI alerts
High impacting Biofrontera Inc. news events
Weekly update
A roundup of the hottest topics
BFRI
News
- Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and ExtremitiesGlobeNewswire
- Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT [Yahoo! Finance]Yahoo! Finance
- Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDTGlobeNewswire
- Biofrontera (NASDAQ:BFRI) had its "buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
- Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
BFRI
Earnings
- 11/12/25 - Miss
BFRI
Sec Filings
- 12/5/25 - Form S-1
- 11/13/25 - Form 8-K
- 11/12/25 - Form 10-Q
- BFRI's page on the SEC website